• In Vitro Drug Response Metrics in Cancer

  2026-08-22

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that drug-induced growth inhibition and cell death are related but non-equivalent response dimensions. Its framework supports more careful assay design, time-course interpretation, and comparison of anticancer agents in cancer biology research.

• Deep Learning for iPSC-CM Cardiotoxicity Screening

  2026-08-22

  Grafton and colleagues developed a deep-learning, high-content imaging workflow that converts phenotypic changes in human iPSC-derived cardiomyocytes into a single cardiotoxicity score. Screening bioactive and diverse chemical libraries showed that the platform can identify liabilities across multiple pharmacological classes and support earlier safety decisions.

• O-propargyl-puromycin (OPP) in B-Cell Translation

  2026-08-21

  O-propargyl-puromycin (OPP) provides a chemical route to measure nascent protein production in B cells. This article explains how to use OPP to distinguish translational suppression from mitochondrial dysfunction, altered cell state, and changes in B-cell composition.

• Human PSC Myogenic Progenitors Engraft Long Term

  2026-08-20

  Khosrowpour et al. show that a defined CD82+ ERBB3+ NGFR+ population from human PSC-derived teratomas can generate durable human dystrophin-positive muscle and establish a dynamic satellite-cell pool after transplantation. The study adds long-term evidence for graft expansion, fiber maturation, and cryopreservation-compatible regenerative potential in a dystrophic xenograft model.

• Fasudil (HA-1077) HCl: ROCK Workflows

  2026-08-20

  Build reproducible ROCK inhibition studies around Fasudil (HA-1077) HCl, from concentration scouting to migration and apoptosis readouts. The workflow also shows how the compound can serve as a complementary perturbation when investigating pathway interactions suggested by recent Hippo-signaling research.

• Axitinib: From VEGFR Potency to Response Phenotypes

  2026-08-19

  Axitinib (AG 013736) is more than a sub-nanomolar VEGFR inhibitor: it is a useful tool for separating pathway suppression, growth arrest, and cell killing. This guide combines target biology with phenotype-aware assay design for more interpretable cancer biology research.

• Alosetron in Intestinal Signaling Assays

  2026-08-19

  Use Alosetron as a selective 5-HT3 receptor antagonist to isolate serotonin-sensitive effects in intestinal epithelial, organoid, motility, and visceral pain signaling research. This workflow pairs receptor-level perturbation with CDC42 polarity, YAP/TAZ, EGFR, and mTOR readouts without overstating an unproven mechanistic connection.

• OM-MSCs, Golgi Stress, and Stroke Recovery

  2026-08-18

  The reference study identifies a mechanistic link between olfactory mucosa mesenchymal stem cells, PEDF secretion, and suppression of Golgi apparatus stress after cerebral ischemia/reperfusion injury. Using complementary cellular and rat models, it shows that PI3K/Akt/mTOR pathway activation is associated with reduced oxidative and calcium stress, Golgi fragmentation, and excessive autophagy.

• Molidustat (BAY85-3934) in HIF Assays

  2026-08-18

  Molidustat (BAY85-3934) gives researchers a controllable way to probe HIF stabilization, erythropoietin stimulation, and hypoxia-linked apoptosis. This workflow connects HIF-PH inhibition with the Septin4–VHL mechanism described in cardiomyocytes while also supporting translational studies of chronic kidney disease anemia and renal anemia therapy.

• (-)-Norepinephrine (+)-bitartrate Workflow Guide

  2026-08-17

  Build more interpretable cardiovascular assays with (-)-Norepinephrine (+)-bitartrate, from fresh-solution preparation to renal perfusion and systemic hemodynamic readouts. The workflow emphasizes receptor-aware controls, sepsis-stage comparisons, and troubleshooting when vascular pressure and renal blood flow diverge.

• Bafilomycin C1 for Phenotypic Screening

  2026-08-17

  Bafilomycin C1 provides a practical way to perturb lysosomal acidification, distinguish autophagy flux from marker accumulation, and add mechanistic depth to high-content screens. When paired with iPSC-derived cardiomyocytes and deep-learning image analysis, it can help separate general cellular stress from pathway-specific phenotypes without replacing direct cardiac safety measurements.

• TG003 Cdc2-like kinase inhibitor Workflows

  2026-08-16

  TG003 enables controlled perturbation of Clk-dependent splicing, from splice-site reporter assays to exon-skipping studies. Its broader Clk and CK1 activity also makes it useful for testing CLK2-linked platinum resistance, provided target engagement is confirmed with orthogonal controls.

• SAR405: Reliable Vps34 Inhibition in Cell Assays

  2026-08-15

  This scenario-based guide shows how SAR405, SKU A8883, can improve interpretation of autophagy, viability, and vesicle-trafficking experiments. It connects biochemical potency, assay compatibility, stock preparation, and vendor-selection criteria to practical laboratory decisions.

• Latrunculin A in Actin–Virus Interaction Studies

  2026-08-14

  Latrunculin A is a reversible inhibitor of actin assembly that can transform cytoskeletal perturbation into a rigorous host-factor assay. This article interprets recent duck enteritis virus research and develops a decision framework for distinguishing actin polymerization, myosin II function, and indirect effects on viral replication.

• Vernakalant for Rapid Atrial Fibrillation Conversion

  2026-08-14

  This phase 3 randomized, placebo-controlled trial evaluated intravenous vernakalant as a rapid pharmacological strategy for converting atrial fibrillation to sinus rhythm. Vernakalant produced substantially faster and more frequent conversion than placebo in short-duration atrial fibrillation, while the safety findings highlight the need for monitored administration and careful patient selection.

8068 records 1/538 page Next 12345 下5页 Last page